AMG 794
Alternative Names: AMG-794Latest Information Update: 26 Jul 2024
At a glance
- Originator Amgen
- Class Antineoplastics; Bispecific antibodies; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Non-small cell lung cancer; Ovarian cancer; Solid tumours
Most Recent Events
- 08 Jul 2024 Amgen terminates a phase I trial in Solid tumours, Ovarian cancer, Non-small cell lung cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Switzerland, Australia (IV), due to business decision to discontinue development of AMG 794 (NCT05317078)
- 28 Feb 2023 Phase-I clinical trials in Non-small cell lung cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Switzerland, Australia (IV) (NCT05317078)
- 28 Feb 2023 Phase-I clinical trials in Ovarian cancer (Inoperable/Unresectable, Metastatic disease, Late-stage disease, Second-line therapy or greater) in Australia, Switzerland (IV) (NCT05317078)